Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174704 · ClinicalTrials.gov registry record
Medication Adherence Research in COPD Patients
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 314
- Enrollment target
NCT03174704: Completed study, sponsored by Johns Hopkins University.
NCT03174704 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 314 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03174704 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 314 participants
- Enrollment target
Study Summary
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death, affects over 24 million people in the US and is the leading cause of disability with projected healthcare costs at almost $50 billion. The goal of this study is to identify novel and potentially powerful targets for behavioral interventions in COPD which has been understudied despite its tremendous detrimental impact on overall public health.
Primary Outcome
Measured by electronic medication monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2023-03-31 |
What the finished NCT03174704 record still lists
NCT03174704 is an observational study that tracks outcomes without assigning an intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03174704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03174704 about?
NCT03174704 is a clinical study titled "Medication Adherence Research in COPD Patients". Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death, affects over 24 million people in the US and is the leading cause of disability with projected healthcare costs at almost $50 billion. The goal of this study is to identify novel and potentially powerful targets for be...
What is the current status of trial NCT03174704?
This trial is currently completed. The enrollment target is 314 participants. The study started on 2017-05-01. Estimated completion is 2023-03-31.
Who is sponsoring clinical trial NCT03174704?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI